This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hausman, S. Z. Articles by Burns, D. L. Search for Related Content PubMed PubMed Citation Articles by Hausman, S. Z. Articles by Burns, D. L.

 Previous Article  |  Next Article 

Infection and Immunity, June 2000, p. 3763-3767, Vol. 68, No. 6
0019-9567/00/$04.00+0

Use of Pertussis Toxin Encoded by ptx Genes from Bordetella bronchiseptica To Model the Effects of Antigenic Drift of Pertussis Toxin on Antibody Neutralization

Sally Z. Hausman and Drusilla L. Burns^*

Laboratory of Respiratory and Special Pathogens, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892

Received 20 December 1999/Returned for modification 11 February 2000/Accepted 27 March 2000

Recently, concern has been voiced about the potential effect that antigenic divergence of circulating strains of Bordetella pertussis might have on the efficacy of pertussis vaccines. In order to model antigenic drift of pertussis toxin, a critical component of many pertussis vaccines, and to examine the effects of such drift on antibody neutralization, we engineered a strain of B. pertussis to produce a variant pertussis toxin molecule that contains many of the amino acid changes found in the toxin encoded by Bordetella bronchiseptica ptx genes. This altered form of the toxin, which is efficiently secreted by B. pertussis and which displays significant biological activity, was found to be neutralized by antibodies induced by vaccination as readily as toxin produced by wild-type B. pertussis. These findings suggest that significant amino acid changes in the pertussis toxin sequence can occur without drastically altering the ability of antibodies to recognize and neutralize the toxin molecule.

---

^* Corresponding author. Mailing address: CBER/FDA, HFM-434, Building 29, Room 418, 8800 Rockville Pike, Bethesda, MD 20892. Phone: (301) 402-3553. Fax: (301) 402-2776. E-mail: burns{at}cber.fda.gov.

---

Infection and Immunity, June 2000, p. 3763-3767, Vol. 68, No. 6
0019-9567/00/$04.00+0

This article has been cited by other articles:

• Preston, A. (2005). Bordetella pertussis: the intersection of genomics and pathobiology. CMAJ 173: 55-62 [Abstract] [Full Text]  
• Kodama, A., Kamachi, K., Horiuchi, Y., Konda, T., Arakawa, Y. (2004). Antigenic Divergence Suggested by Correlation between Antigenic Variation and Pulsed-Field Gel Electrophoresis Profiles of Bordetella pertussis Isolates in Japan. J. Clin. Microbiol. 42: 5453-5457 [Abstract] [Full Text]  
• Tsang, R. S. W., Lau, A. K. H., Sill, M. L., Halperin, S. A., Van Caeseele, P., Jamieson, F., Martin, I. E. (2004). Polymorphisms of the Fimbria fim3 Gene of Bordetella pertussis Strains Isolated in Canada. J. Clin. Microbiol. 42: 5364-5367 [Abstract] [Full Text]  
• van Loo, I. H. M., Mooi, F. R. (2002). Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology 148: 2011-2018 [Abstract] [Full Text]  
• Weber, C., Boursaux-Eude, C., Coralie, G., Caro, V., Guiso, N. (2001). Polymorphism of Bordetella pertussis Isolates Circulating for the Last 10 Years in France, Where a Single Effective Whole-Cell Vaccine Has Been Used for More than 30 Years. J. Clin. Microbiol. 39: 4396-4403 [Abstract] [Full Text]